Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy
about
sameAs
Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factorsAutocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cellsInterleukin-1beta induced vascular permeability is dependent on induction of endothelial tissue factor (TF) activityMesenchymal Stem Cell-Mediated Effects of Tumor Support or SuppressionTargeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signalingPhage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects.Endothelial cell Bcl-2 and lymph node metastasis in patients with oral squamous cell carcinoma.Leukemia regression by vascular disruption and antiangiogenic therapy.DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4).Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents.Impact of VEGF-C gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan.Murine Lewis lung carcinoma-derived endothelium expresses markers of endothelial activation and requires tumor-specific extracellular matrix in vitro.Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.Does Chemotherapy Change Expression of VEGF A&C and MVD in Acute Myeloid Leukemia?Contribution of bone microenvironment to leukemogenesis and leukemia progression.Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide.Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.Role of vascular endothelial growth factor receptor-3/Flt-4 in early-stage cervical cancer.PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma.The role of the VEGF-C/VEGFR-3 axis in cancer progression.Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.Sentinel node and mechanism of lymphatic metastasis.Clinicopathological Significance of VEGF-C, VEGFR-3 and Cyclooxygenase-2 in Early-Stage Cervical Cancer.Autocrine VEGF loops, signaling pathways, and acute leukemia regulation.One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment.Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells.The non-canonical role of vascular endothelial growth factor-C axis in cancer progressionRelationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?Gene Expression of VEGF-A and VEGF-C in Peripheral Blood Mononuclear Cells of Iranian Patients with Acute Myeloid Leukemia.Mesenchymal stromal cells derived from the bone marrow of acute lymphoblastic leukemia patients show altered BMP4 production: correlations with the course of disease.Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells.A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface.Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.Vascular endothelial growth factor signaling in acute myeloid leukemia.Targeting the vascular endothelial growth factor in hematologic malignancies.(Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia.
P2860
Q24303560-9D36DBD5-9309-4670-9954-5D4A1FB12429Q24318473-C671EA58-539A-405B-971F-3B8279E3CD6CQ24813092-C6153CD8-4C99-455F-950D-4DD2BB308F7FQ26773413-53B702FF-A6B4-42BF-B626-862E17BA1BBEQ28078716-C77AB468-AF3F-4C42-8B07-B93745C1E14DQ33651167-8E5755A1-C8C9-4727-8652-38A64E6389DAQ33977081-02F7F087-453C-4AA9-9B24-9B017620D122Q34026770-05C52334-9591-47D1-885B-F28085DF0187Q34124965-94CCCDD1-21AC-49D9-A5DA-AA7AB9706A4FQ34129693-C15522EE-E457-4850-B94B-9766B50E916EQ34660821-92B07121-EF7C-4F01-9D36-B9761F1F0185Q34672891-89D966F6-BCF7-4EBF-9ECA-FB7943BFBBC9Q34771689-D13BD76B-77AD-4F74-85C4-D87D316A8BD8Q35000353-FE900097-6103-47F2-A056-6701F6A9F8ABQ35009275-CB85976B-9C99-47F0-8C1A-6832C076811CQ35037058-5B2B5599-053A-4915-A843-1C1BD8F7DB99Q35567260-6C2CE6B7-DE89-4FB9-B34B-1A0E73BE437DQ35569079-69E21AD5-E1C8-4D05-A3D8-BC420AE71FC4Q35740199-21C6394F-2AC8-4F8F-8B68-9705F7FC80E3Q36006453-B445798A-E071-4750-BA41-D7490ADEA052Q36216694-66E55FED-F05C-462D-9562-0AB1716E73E8Q36506366-1A485A06-933B-4E0F-BBDC-72A9784FA75DQ36609889-BCCA3C8E-C51E-4275-89A0-329A0AC95925Q36611320-67C8D49F-D9AD-428F-81C4-C1A7259B545DQ36679422-75EC160D-A1A5-4AB8-A82D-2B59E15C6010Q36735345-1A960A74-153E-46C8-AEBA-A23A1FEB4F3BQ36799838-78221B9F-AFC0-481A-B174-0101198CAB7EQ36958177-44771F2F-903A-41A5-80D1-3888FB37C969Q37028329-616C0FB1-C67F-4433-8B1A-7D8B4862AF09Q37071029-BCC36FE2-8F56-450B-8F5F-85A592F93A88Q37094060-C0D78FC9-035E-4CE9-AC9E-994DE1021D40Q37426395-87B9C32C-E271-4E26-A514-1178431C6EB6Q37439242-57C8B611-0E89-482E-8A33-3FB6A8330E7BQ37551677-DBB0C4AE-9EE2-4815-AB55-8546450F5C0DQ37681007-9AEF8181-A1B5-469F-8A67-97C2824FE516Q37728960-085A1554-B82B-43E6-A6FF-78821D0F6AE1Q37739569-874B155A-FEA9-454E-8133-5C99C8B3A003Q38029546-FA6F9FE1-8D3E-4B4D-A9CC-04B632FDD952Q38038645-9AAE9432-8D6D-42D8-AD28-B2F3198CAE0CQ38269954-5791BE84-2EC8-4B7B-8CC6-97F2BC7762B4
P2860
Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Vascular endothelial growth fa ...... and resistance to chemotherapy
@ast
Vascular endothelial growth fa ...... and resistance to chemotherapy
@en
Vascular endothelial growth fa ...... and resistance to chemotherapy
@nl
type
label
Vascular endothelial growth fa ...... and resistance to chemotherapy
@ast
Vascular endothelial growth fa ...... and resistance to chemotherapy
@en
Vascular endothelial growth fa ...... and resistance to chemotherapy
@nl
prefLabel
Vascular endothelial growth fa ...... and resistance to chemotherapy
@ast
Vascular endothelial growth fa ...... and resistance to chemotherapy
@en
Vascular endothelial growth fa ...... and resistance to chemotherapy
@nl
P921
P356
P1433
P1476
Vascular endothelial growth fa ...... and resistance to chemotherapy
@en
P2093
Margaret Choy
Shahin Rafii
P304
P356
10.1182/BLOOD.V99.6.2179
P407
P577
2002-03-15T00:00:00Z